UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders

Journal of medicinal chemistry, 2018-10, Vol.61 (20), p.9062-9084

2018

Volltextzugriff (PDF)

The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

ChemMedChem, 2019-07, Vol.14 (13), p.1238-1247

2019

Volltextzugriff (PDF)

Sotorasib: First Approval

Drugs (New York, N.Y.), 2021-09, Vol.81 (13), p.1573-1579

Blair, Hannah A.

2021

Volltextzugriff (PDF)

The role of kinetic context in apparent biased agonism at GPCRs

Nature communications, 2016-02, Vol.7 (1), p.10842-10842, Article 10842

2016

Volltextzugriff (PDF)

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

The New England journal of medicine, 2014-11, Vol.371 (22), p.2141-2142

2014

Volltextzugriff (PDF)

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8), p.2045-2056

2012

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice

Scientific reports, 2019-03, Vol.9 (1), p.4522, Article 4522

2019

Volltextzugriff (PDF)

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Clinical cancer research, 2017-09, Vol.23 (18), p.5366-5373

2017

Volltextzugriff (PDF)

Differentiating Drug-Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.549-558

2014

Volltextzugriff (PDF)

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Clinical cancer research, 2016-10, Vol.22 (20), p.5130-5140

2016

Volltextzugriff (PDF)

Design, synthesis, and AChE inhibitory activity of new benzothiazole–piperazines

Bioorganic & medicinal chemistry letters, 2016-11, Vol.26 (22), p.5387-5394

2016

Volltextzugriff (PDF)

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

The New England journal of medicine, 2009-07, Vol.361 (2), p.123-134

2009

Volltextzugriff (PDF)

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Blood, 2008-04, Vol.111 (8), p.4022-4028

2008

Volltextzugriff (PDF)

Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

Journal of cerebral blood flow and metabolism, 2017-09, Vol.37 (9), p.3110-3123

2017

Volltextzugriff (PDF)

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Journal of medicinal chemistry, 2015-08, Vol.58 (16), p.6348-6358

2015

Volltextzugriff (PDF)

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Annals of oncology, 2017-03, Vol.28 (3), p.512-518

2017

Volltextzugriff (PDF)

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study

Journal of the American College of Cardiology, 2013-04, Vol.61 (15), p.1601-1606

2013

Volltextzugriff (PDF)

Olmutinib: First Global Approval

Drugs (New York, N.Y.), 2016-07, Vol.76 (11), p.1153-1157

Kim, Esther S.

2016

Volltextzugriff (PDF)

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Clinical cancer research, 2012-01, Vol.18 (2), p.568-576

2012

Volltextzugriff (PDF)

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

Blood, 2021-01, Vol.137 (1), p.115-125

2021

Volltextzugriff (PDF)

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Science (American Association for the Advancement of Science), 2019-03, Vol.363 (6431)

2019

Volltextzugriff (PDF)

Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace

Neuropharmacology, 2018-05, Vol.134 (Pt A), p.101-107

2018

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.229-241

2019

Volltextzugriff (PDF)

An Activatable Cancer-Targeted Hydrogen Peroxide Probe for Photoacoustic and Fluorescence Imaging

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (20), p.5407-5417

2019

Volltextzugriff (PDF)

1 – 25 von 2.914

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.724)
Mit Volltextzugriff
(2.301)

Publikationsform

Artikel
(2.912)
magazinearticle
(2)

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.355)
Life Sciences & Biomedicine
(2.315)
Piperazines - Pharmacokinetics
(2.147)
Humans
(2.047)
Male
(1.615)
Pharmacology & Pharmacy
(1.390)
Animals
(1.318)
Biological And Medical Sciences
(1.132)
Medical Sciences
(1.071)
Pharmacology. Drug Treatments
(887)
Female
(868)
Piperazines - Pharmacology
(868)
Adult
(776)
Rats
(702)
Piperazines - Administration & Dosage
(655)
Piperazines - Therapeutic Use
(647)
Middle Aged
(565)
Pharmacokinetics
(562)
Piperazines - Adverse Effects
(459)
Piperazines - Blood
(424)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders

The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

Sotorasib: First Approval

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

The role of kinetic context in apparent biased agonism at GPCRs

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Differentiating Drug-Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Design, synthesis, and AChE inhibitory activity of new benzothiazole–piperazines

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study

Olmutinib: First Global Approval

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

An Activatable Cancer-Targeted Hydrogen Peroxide Probe for Photoacoustic and Fluorescence Imaging

Suchergebnisse filtern